| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01613469 Details | 2018-08-16 Interventional | 2 | 5 | Leucovorin Rectal Neoplasm… | Re-eval of patient population - | |||
| NCT01294683 2010-023939-42 Details | 2018-08-16 Interventional | 3 | 977 | Niacin Niacinamide Nicotinic Acids Simvastatin Dyslipidemias Hypercholestero… Dyslipidemia Primary Hyperch… | - - | |||
| NCT01274559 Details | 2018-08-16 Interventional | 3 | 1173 | Niacin Dyslipidemias Hypercholestero… Mixed Dyslipide… Primary Hyperch… | In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a
significant increase in incidence of some types of non-fatal SAEs MK-0524A-133 was stopped prior to completion. Raw individual efficacy data were obtained but none of planned efficacy outcomes were summarized or analyzed. Only safety data were summarized. | |||
| NCT01243762 Details | 2018-08-16 Interventional | 1 | [1 Refs] | 47 | 3-(4-((4-chloro… Neoplasms Neoplasms Malig… | The study was terminated for business reasons and not due to any safety or efficacy concerns
related to dalotuzumab. The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab. | ||
| NCT00800137 Details | 2018-08-15 Interventional | 4 | [1 Refs] | 984 | Calcium heparin Dalteparin Heparin Heparin, Low-Mo… Tinzaparin Warfarin Hematoma | At time of pre-specified 2nd interim analysis - | ||
| NCT03377101 Details | 2018-08-14 Interventional | 2 | 0 | Fulvestrant Palbociclib Breast Neoplasm… Estrogen Recept… HER2/Neu Negati… Progesterone Re… Stage IV Breast… | change in study design. - | |||
| NCT03227432 Details | 2018-08-14 Interventional | 2 | 0 | Dexamethasone Elotuzumab Nivolumab Pomalidomide Multiple Myelom… Neoplasms, Plas… | Withdrawn before enrollment due to issues around the FDA hold on PD-1/PD-L1 drugs in
combination with IMIDs. - | |||
| NCT03143530 Details | 2018-08-14 Interventional | 4 | 0 | Ropivacaine Agnosia Analgesia, Post… Mastectomy Nerve Block | Extensive protocol revisions initiated. - | |||
| NCT02351037 Details | 2018-08-14 Interventional | 2 | 36 | Azacitidine Ibrutinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Study data do not support development in AML. - | |||
| NCT01911325 2013-000833-11 Details | 2018-08-14 Interventional | 1 | 27 | Docetaxel Carcinoma, Non-… Lung Neoplasms Squamous Non-sm… | Review of safety and preliminary efficacy data showed marginal anti-tumor activity. - | |||
| NCT01907802 NCT02925689 Details | 2018-08-14 Interventional | 1 | 8 | Dabrafenib Renal Insuffici… BRAF Gene Mutat… Hepatic Complic… Renal Failure Solid Neoplasm | - - | |||
| NCT03200080 Details | 2018-08-13 Interventional | 1 | 26 | Amphetamine Dextroamphetami… Abuse Potential | New Safety Information - | |||
| NCT01690325 Details | 2018-08-13 Interventional | 2 | 21 | Bevacizumab Cyclophosphamid… Docetaxel Epirubicin Trastuzumab Breast Neoplasm… Breast Cancer | Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment
behind planned schedule and challenges of site performance - | |||
| NCT01648101 Details | 2018-08-13 Interventional | 3 | 76 | Ezogabine Epilepsy Seizures | Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam RTG114855 was designed for registration of retigabine as add-on treatment of drug-resistant POS in South Korea/Taiwan/ Vietnam. GSK decided not to pursue registration in these countries and terminated the study early based on new safety information. | |||
| NCT00950261 Details | 2018-08-13 Interventional | 2 | 0 | Cisplatin Uterine Cervica… Cervical Neopla… | A competing trial has been initiated. - | |||
| NCT00697034 Details | 2018-08-13 Interventional | 4 | 12 | Capsaicin Psoriasis | Lack of qualified and willing volunteers. - | |||
| NCT02672358 Details | 2018-08-10 Interventional | 2 | 0 | Dabrafenib Trametinib Carcinoma, Non-… Lung Neoplasms Non-Small-Cell … | Company Decision - | |||
| NCT02343263 Details | 2018-08-10 Interventional | 2 | 18 | Bupivacaine Fibrin Tissue A… Hemorrhage Pain, Postopera… Postoperative H… | FDA IND was not obtained study closed due to need for FDA investigational new drug application. | |||
| NCT00104806 Details | 2018-08-10 Interventional | 2 | 5 | Arsenic Trioxid… Cholecalciferol Vitamin D Myelodysplastic… Myelodysplastic… Myeloproliferat… Preleukemia Syndrome Leukemia Myelodysplastic… | sponsor discontinues support - | |||
| NCT03009058 Details | 2018-08-09 Interventional | 1/2 | 2 | Albumin-Bound P… Capecitabine Cetuximab Cyclophosphamid… Fluorouracil Folic Acid Gemcitabine Ipilimumab Irinotecan Leucovorin Levoleucovorin Nivolumab Oxaliplatin Pembrolizumab Neoplasm Metast… Metastatic Canc… | Commercial reasons - |